Minicircle DNA-Engineered CAR T Cells Suppressed Tumor Growth in Mice

被引：13

作者：

Han, Jinsheng ^{[1
]}

Gao, Fei ^{[1
,2
]}

Geng, Songsong ^{[4
]}

Ye, Xueshuai ^{[1
]}

Wang, Tie ^{[3
,4
]}

Du, Pingping ^{[4
]}

Cai, Ziqi ^{[4
]}

Fu, Zexian ^{[5
]}

Zhao, Zhilong ^{[6
]}

Shi, Long ^{[7
]}

Li, Qingxia ^{[2
]}

Cai, Jianhui ^{[1
,2
]}

机构：

[1] Hebei Med Univ, Dept Surg, Shijiazhuang, Hebei, Peoples R China

[2] Hebei Gen Hosp, Dept Surg & Oncol, Shijiazhuang, Hebei, Peoples R China

[3] Hebei HOFOY Biotech Co Ltd, Hebei Engn Technol Res Ctr Cell Therapy, Shijiazhuang, Hebei, Peoples R China

[4] Hebei Cangzhou Hosp Integrated Tradit Chinese & W, Dept Surg, Cangzhou, Hebei, Peoples R China

[5] Hebei Engn Univ, Dept Surg, Affiliated Hosp, Handan, Hebei, Peoples R China

[6] Jinzhou Med Univ, Dept Surg, Affiliated Hosp 3, Jinzhou, Liaoning, Peoples R China

[7] Hebei Med Univ, Dept Oncol, Hosp 2, Shijiazhuang, Hebei, Peoples R China

来源：

MOLECULAR CANCER THERAPEUTICS | 2020年 / 19卷 / 01期

关键词：

CHIMERIC ANTIGEN RECEPTOR; EXPRESSION; VECTOR; TRANSPOSON; THERAPY;

D O I：

10.1158/1535-7163.MCT-19-0204

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Viral-based chimeric antigen receptor-engineered T (CAR T)-cell manufacturing has potential safety risks and relatively high costs. The nonviral minicircle DNA (mcDNA) is safer for patients, cheaper to produce, and may be a more suitable technique to generate CAR T cells. In this study, we produced mcDNA-based CAR T cells specifically targeting prostate stem cell antigen (PSCA; mcDNA-PSCA-CAR T cells). Our results showed that mcDNA-PSCA-CAR T cells persisted in mouse peripheral blood as long as 28 days and demonstrated more CAR T-cell infiltration, higher cytokine secretion levels, and better antitumor effects. Together, our results suggest that mcDNA-CAR can be a safe and cost-effective platform to produce CAR T cells.

引用

页码：178 / 186

页数：9

共 50 条

[41] TCR engineered T cells for solid tumor immunotherapy
Yikai Zhang
Zhipeng Liu
Wei Wei
Yangqiu Li
Experimental Hematology & Oncology, 11
[42] Trafficking of CAR-Engineered Human T Cells Following Regional or Systemic Adoptive Transfer in SCID Beige Mice
Ana Caterina Parente-Pereira
Jerome Burnet
David Ellison
Julie Foster
David Marc Davies
Sjoukje van der Stegen
Sophie Burbridge
Laura Chiapero-Stanke
Scott Wilkie
Stephen Mather
John Maher
Journal of Clinical Immunology, 2011, 31 : 710 - 718
[43] Preparation of TSTA.tumor specific minicircle DNA vector for targeted expression in cancer cells
Chanani, P.
Ata-abadi, N. Sanei
Dormiani, K.
Rezaei, N.
Nasr-Esfahani, M. H.
EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 472 - 472
[44] CAR-Macrophages and CAR-T Cells Synergistically Kill Tumor Cells In Vitro
Liu, Maoxuan
Liu, Junchen
Liang, Ziwei
Dai, Kun
Gan, Jiangyu
Wang, Qi
Xu, Yang
Chen, Youhai H.
Wan, Xiaochun
CELLS, 2022, 11 (22)
[45] Engineered hypoimmune allogeneic CAR T cells as potential off-the-shelf CAR T cell immunotherapies.
Hu, Xiaomeng
White, Kathy
Gattis, Corie
Clarke, Ryan
Landry, Sam
Basco, Ron
Tham, Eleonore
Luo, Emily
Tucker, Andrew
Bandoro, Christopher
Chu, Elaine
Young, Chi
Manner, Karl
Nho, Priscilla
Lam, Ben
Beauchesne, Pascal
Foster, Aaron
Dowdle, William E.
Rebar, Edward J.
Fry, Terry J.
Schrepfer, Sonja
CANCER RESEARCH, 2022, 82 (12)
[46] Trafficking of CAR-Engineered Human T Cells Following Regional or Systemic Adoptive Transfer in SCID Beige Mice
Parente-Pereira, Ana Caterina
Burnet, Jerome
Ellison, David
Foster, Julie
Davies, David Marc
van der Stegen, Sjoukje
Burbridge, Sophie
Chiapero-Stanke, Laura
Wilkie, Scott
Mather, Stephen
Maher, John
JOURNAL OF CLINICAL IMMUNOLOGY, 2011, 31 (04) : 710 - 718
[47] CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice
Li, Nan
Torres, Madeline B.
Spetz, Madeline R.
Wang, Ruixue
Peng, Luyi
Tian, Meijie
Dower, Christopher M.
Nguyen, Rosa
Sun, Ming
Tai, Chin-Hsien
de Val, Natalia
Cachau, Raul
Wu, Xiaolin
Hewitt, Stephen M.
Kaplan, Rosandra N.
Khan, Javed
St Croix, Brad
Thiele, Carol J.
Ho, Mitchell
CELL REPORTS MEDICINE, 2021, 2 (06)
[48] Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy
Chen, Pei-Hsuan
Lipschitz, Mikel
Weirather, Jason L.
Jacobson, Caron
Armand, Philippe
Wright, Kyle
Hodi, F. Stephen
Roberts, Zachary J.
Sievers, Stuart A.
Rossi, John
Bot, Adrian
Go, William
Rodig, Scott J.
JCI INSIGHT, 2020, 5 (12)
[49] In vivo generated human CAR T cells eradicate tumor cells
Agarwal, Shiwani
Weidner, Tatjana
Thalheimer, Frederic B.
Buchholz, Christian J.
ONCOIMMUNOLOGY, 2019, 8 (12):
[50] Differential growth of IFN-β-engineered tumor cells in nude and IFN receptor-null mice
Zhang, FH
Lee, J
Wang, DR
Dong, ZY
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2006, 26 (02): : 108 - 118

← 1 2 3 4 5 →